Codexis, Inc. (CDXS) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects positive sentiment due to improved financial performance, cost management, and optimistic guidance. The company reported a significant net income improvement, reduced expenses, and a strong cash position. Additionally, the strategic shift towards ECO Synthesis and promising collaborations suggest future growth. Despite some speculative elements in revenue guidance, the overall outlook is positive with anticipated revenue growth and strategic partnerships.
Key Financial Performance
Total revenues (Q4 2025) $38.9 million, a significant increase from $21.5 million in Q4 2024. The increase was primarily due to the Merck technology transfer agreement executed in Q4 2025.
Total revenues (FY 2025) $70.4 million, up from $59.3 million in FY 2024. The increase was driven by the Merck technology transfer agreement and other revenue growth.
Product gross margin (Q4 2025 and FY 2025) 64%, compared to 56% in FY 2024. The improvement was due to a favorable product mix and the replacement of low-margin products with more profitable ones.
R&D expenses (Q4 2025) $11.7 million, slightly down from $12.1 million in Q4 2024, due to lower employee-related costs and stock-based compensation expenses.
R&D expenses (FY 2025) $52.3 million, up from $46.3 million in FY 2024. The increase was due to higher employee-related costs, lab supplies expenses, and reclassification of certain employees to R&D, partially offset by a decrease in outside services.
SG&A expenses (Q4 2025) $11.2 million, down from $13 million in Q4 2024, due to lower employee-related costs and reduced use of outside services.
SG&A expenses (FY 2025) $47.1 million, down from $55.1 million in FY 2024. The decrease was due to lower stock-based compensation expenses, legal expenses, and reduced use of outside services.
Net income (Q4 2025) $9.6 million, compared to a loss of $10.4 million in Q4 2024. The improvement was driven by increased revenues and cost management.
Net loss (FY 2025) $44 million, an improvement from a loss of $65.3 million in FY 2024, due to higher revenues and cost reductions.
Cash position (end of FY 2025) $78.2 million, sufficient to fund planned operations and capital expenditures through the end of 2027.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ECO Synthesis manufacturing platform: Developed to address challenges in siRNA production technology. Demonstrated capability to synthesize 10 grams of siRNA using full sequential ECO Synthesis. Currently scaling up production to 100-gram scale and targeting 0.5-kilogram scale by year-end 2026.
Stereoisomer control in siRNA: Introduced a new feature to generate siRNA with specific stereochemical control, potentially improving potency and purity of products.
siRNA production technology market: Estimated total addressable annual market of $2 billion in 5 years. Codexis aims to establish itself as a key technology provider.
Customer engagement: Engaged with 40 companies and 55 opportunities in the sales pipeline for ECO Synthesis technology. Signed three CDMO agreements in 2025 with Bachem, Nitto Avecia, and Axolabs.
Production infrastructure: Modernized non-GMP production capability in Redwood City, achieving ISO 9001 certification. Passed facility and quality management inspection by a large pharmaceutical customer.
GMP facility: Leased a new GMP plant in 2025, with construction to begin in the second half of 2026 and full operation expected by the end of 2027.
Cost management: Realigned workforce in Q4 2025 to reduce expenditures, partially offsetting GMP facility costs.
Revenue growth and profitability: Achieved $38.9 million in Q4 2025 revenue, driven by a $37.8 million technology transfer agreement with Merck. Expecting 2026 revenue of $72-76 million.
Small molecule biocatalysis business: Returned to healthy profit margins in 2025, supporting investment in ECO Synthesis. Stable pipeline of late-stage clinical drugs expected to fuel growth for 3-5 years.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
siRNA production scalability: Current production technologies for siRNA medicines are unable to keep up with the growing demand, which could compromise the impact of these therapies if they cannot be produced at scale.
Supply chain robustness: The company is still in the process of building a robust supply chain to support its ECO Synthesis platform, which could pose risks to timely and efficient production.
GMP facility readiness: The GMP facility retrofit construction is not expected to be fully operational until the end of 2027, potentially delaying the adoption of the ECO Synthesis platform for GMP siRNA production.
Workforce realignment: The company had to realign its workforce in the fourth quarter of 2025 to manage expenditures, which could impact employee morale and operational efficiency.
Revenue dependency on new contracts: The company’s financial success in 2026 heavily depends on signing new contracts and licensing deals, which introduces uncertainty.
Economic uncertainties: The company’s ability to fund operations and capital expenditures through 2027 is contingent on current cash reserves and revenue projections, which could be impacted by broader economic conditions.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: 2026 revenue is expected to be in the range of $72 million to $76 million, with revenue more heavily weighted towards the second half of the year.
Capital Expenditures: Planned increase in capital expenditures associated with the GMP facility build-out, with construction beginning in the second half of 2026 and expected to be fully operational by the end of 2027.
Market Trends and Growth: The total addressable annual market for siRNA production technologies is estimated to reach $2 billion in 5 years, with the number of siRNA medicines in development growing at a rate of 5% to 10% per year.
Operational Scaling: Scaling up the ECO Synthesis manufacturing platform to 0.5 kilogram scale by the end of 2026.
Customer Engagement: 55 opportunities in the sales pipeline with 40 individual companies showing strong interest in the ECO Synthesis technology. A new contract with an emerging biotech company involves supplying 50 grams of siRNA material for preclinical testing, with potential for clinical studies.
Strategic Partnerships: Expecting to sign new multiyear agreements with customers, including licensing fees, milestone payments, and clinical supply agreements. Also planning to sign a licensing deal in 2026 similar to the Merck agreement in 2025.
Innovation and Product Development: Focus on stereoisomer control in siRNA manufacturing, with plans to showcase advancements at the TIDES meeting in 2026. This development could become a significant product offering.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Could you talk about the potential value for stereoisomer control and when it might be validated preclinically or clinically? Are any of your existing 55 opportunities exploring this?
A:The company is actively examining the biological activity of stereo configurations using the ECO Synthesis platform. Substantive data will be presented at the TIDES U.S. meeting, and further work will be done throughout the year to associate these configurations with improved potency. Conversations with customers with siRNA pipelines are ongoing, and collaborations are being explored. The company anticipates significant activity in this area for 2026 and beyond.
Q:Could you explain the general process of how the recently announced deal came about?
A:The deal involves a small organization with a cardiovascular asset that faced challenges unmet by the current industry. Discussions have been ongoing for months, and the ECO Synthesis manufacturing platform is expected to meet their needs. The collaboration aims to deliver materials for clinical assets, progressing through clinical trials and eventually into commercial production.
Q:Could you walk us through the process of the 50-gram contract and its potential future phases?
A:The 50-gram contract began as a feasibility study to assess the compatibility of the ECO Synthesis platform with the client's sequence and construct. The client will use the delivered material for preclinical studies and comparability assessments. If successful, the client may progress to IND submission, toxicology material production, and clinical trials. The company aspires to become the manufacturing partner, providing commercial material if the asset advances through development.
Q:How should we think about the revenue potential as the 50-gram contract scales through development?
A:The company aims to build a portfolio of similar customers and expects licensing deals and technology commitments to generate significant revenue. After the GMP facility becomes operational, the company will sell products and potentially license the technology. Smaller companies may purchase GMP siRNA directly. If the technology delivers superior assets, it could increase value for the company and shareholders.
Q:What type of visibility do you have into the $72 million to $76 million revenue guidance for this year?
A:The revenue projections are based on historical buying practices and estimates. While some projections are speculative, a large percentage of the business has line of sight. The company acknowledges that early-year projections always include some unknowns.
Q:Where does the industry stand in terms of total siRNA demand, and what is the outlook?
A:The siRNA therapeutics pipeline is vibrant, with 8 commercial assets and growing clinical trial numbers. Demand estimates range from 10 to 30 metric tons of oligonucleotide material by 2030. The company aims to capture a significant share of this market.
Q:How much gross margin variability do you see with the mix of outsourced business versus partners taking ECO in-house?
A:The ECO business primarily involves services, so gross margin is calculated on product sales, mainly from the biocatalysis business. The gross margin has been stable at 64% for the year, and the company expects it to remain stable through 2026.
Q:How should we think about the revenue mix and growth split between the legacy biocatalysis business and the ECO business?
A:The ECO business is expected to drive the bulk of growth, while the small molecule biocatalysis business has stabilized. The biocatalysis pipeline includes late-stage clinical products, which will fuel growth, but the higher growth rate is anticipated from the ECO side of the business.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numerical details about the revenue potential as the 50-gram contract scales through development, using vague language like 'significant revenue' and 'increased value.' Additionally, the response to the revenue guidance question acknowledged speculative projections without detailing the percentage of known versus speculative revenue.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ECO Synthesis
Merck
RD
Synthesis manufacturing
Synthesis platform
Synthesis product
achievement
activity
addition
agreement licensing
arrangement
asset
capital expenditure
certification
customer ECO
drug candidate
end siRNA
expenditure end
feasibility
goal
gram siRNA
industry
licensing fee
margin product
milestone platform
moment
need
period
platform gram
practice licensing
product service
production capability
production technology
reorganization
result CFO
saving
stage
stereoisomer
study
supply agreement
technology transfer
testing
value
CDXS Transcript
Codexis, Inc. (CDXS) Q4 2025 Earnings Call Transcript
Positive3-11
The earnings call reflects positive sentiment due to improved financial performance, cost management, and optimistic guidance. The company reported a significant net income improvement, reduced expenses, and a strong cash position. Additionally, the strategic shift towards ECO Synthesis and promising collaborations suggest future growth. Despite some speculative elements in revenue guidance, the overall outlook is positive with anticipated revenue growth and strategic partnerships.
Codexis, Inc. (CDXS) Q3 2025 Earnings Call Transcript
Unknown11-7
The earnings call reveals several concerns: a significant revenue decline, increased R&D expenses, and dependence on a single agreement for financial stability. Despite improved gross margins and a slight reduction in net loss, the transition risks, potential revenue drop, and economic uncertainties weigh heavily. The Q&A session offered no new positive insights and highlighted challenges, such as siRNA revenue not offsetting legacy declines. Given these factors, the stock is likely to experience a negative reaction, potentially in the range of -2% to -8%.
Codexis, Inc. (CDXS) Q2 2025 Earnings Call Transcript
Positive8-13
The earnings call highlights several positive aspects: improved product gross margins, reduced net loss, and a solid cash position. The Q&A session indicates a growing pipeline and strategic focus on high-value opportunities. However, management's vague responses on capacity expansion and revenue growth create some uncertainty. Despite this, the overall sentiment is positive due to strong financial performance and strategic initiatives. The absence of negative catalysts like revenue misses or new secondary offerings further supports a positive outlook.
Earnings call transcript: Codexis Q1 2025 results miss forecasts, stock declines
Unknown5-14
The earnings call reveals several negative indicators: a significant revenue decline, increased net loss, competitive pressures, and lack of a shareholder return plan. Although gross margins improved, the absence of a buyback or dividend program and unclear management responses during the Q&A contribute to uncertainty. The projected cash flow positivity by 2026 is optimistic but lacks immediate catalysts. These factors suggest a negative sentiment, likely resulting in a stock price decline of -2% to -8% over the next two weeks.
CDXS Slides
CDXS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
